|
業務類別
|
Biotechnology |
|
業務概覽
|
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. |
| 公司地址
| 7 Times Square, Suite 2503, New York, NY, USA, 10036 |
| 電話號碼
| +1 646 200-5278 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.sellaslifesciences.com |
| 員工數量
| 13 |
| Dr. Angelos M. Stergiou, M.D.,Sc.D. |
Director, President and Chief Executive Officer |
美元 676.00K |
23/04/2026 |
| Dr. Dragan Cicic, M.D. |
Senior Vice President and Chief Development Officer |
美元 451.23K |
23/04/2026 |
| Mr. John T. Burns, C.P.A. |
Senior Vice President, Chief Financial Officer and Principal Accounting Officer |
美元 429.61K |
23/04/2026 |
|
|
| Ms. Jane Wasman, J.D. |
Independent Director |
23/04/2026 |
| Dr. David A. Scheinberg,M.D.,PhD |
Independent Director |
23/04/2026 |
| Mr. John Varian |
Chairman of the Board |
23/04/2026 |
| Mr. Robert L. Van Nostrand |
Independent Director |
23/04/2026 |
| Dr. Angelos M. Stergiou, M.D.,Sc.D. |
Director, President and Chief Executive Officer |
23/04/2026 |
| Ms. Katherine Bach Kalin, M.B.A. |
Independent Director |
23/04/2026 |
|
|
|
|
